Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma

Cancer Investigation

Volumn 27, Issue 5, 2009, Pages 521-528

  Boidot, Romain ^a   Végran, Frédérique ^a,d   Soubeyrand, Marie Sophie ^b   Fumoleau, Pierre ^c   Coudert, Bruno ^c   Lizard Nacol, Sarab ^a  

^a Chu   (France)

^b Laboratory of Pathology   (France)

^c Laboratoire de Biochimie Médicale   (France)

^d University of Medical School   (Belgium)

Author keywords

Apoptosis; Breast cancer; Cell cycle; Gene expression; Neoadjuvant chemotherapy; Stress

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; MESSENGER RNA; TAXOID; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GENE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR BIOPSY; ADJUVANT THERAPY; BREAST TUMOR; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG CARCINOMA; METABOLISM; PAGET NIPPLE DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67449083878     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802298096     Document Type: Article

References (31)

1. van der Hage, J.A.; van de Velde, C.J.; Julien, J.P.; Tubiana-Hulin, M.; Vandervelden, C.; Duchateau, L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19(22), 4224-4237. (Pubitemid 33081640)
2. Launchbury, A.P.; Habboubi, N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity, and toxicity. Cancer Treat Rev 1993, 19(3), 197-228.
3. Amat, S.; Bougnoux, P.; Penault-Llorca, F.; Fétissof, F.; Curé, H.; Kwiatkowski, F.; Achard, J.L.; Body, G.; Dauplat, J.; Chollet, P. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003, 88(9), 1339-1345. (Pubitemid 36606412)
4. Airoldi, M.; Cattel, L.; Pedani, F.; Marchionatti, S.; Tagini, V.; Bumma, C.; Recalenda, V. Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer. Breast Cancer Res Treat 2001, 70(3), 185-195.
5. Sotiriou, C.; Powles, T.J.; Dowsett, M.; Jazaeri, A.A.; Feldman, A.L.; Assersohn, L.; Gadisetti, C.; Libutti, S.K.; Liu, E.T. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002, 4(3), R3.
6. Chang, J.C.; Wooten, E.C.; Tsimelzon, A.; Hilsenbeck, S.G.; Gutierrez, M.C.; Elledge, R.; Mohsin, S.; Osborne, C.K.; Chamness, G.C.; Allred, D.C.; O'Connell, P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet2003, 362(9381), 362-369.
7. Ayers, M.; Symmans, W.F.; Stec, J.; Damokosh, A.I.; Clark, E.; Hess, K.; Lecocke, M.; Metivier, J.; Booser, D.; Ibrahim, N.; Valero, V.; Royce, M.; Arun, B.; Whitman, G.; Ross, J.; Sneige, N.; Hortobagyi, G.N.; Pusztai, L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004, 22(12), 2284-2293. (Pubitemid 41115384)
8. Folgueira, M.A.; Carraro, D.M.; Brentani, H.; Patrão, D.F.; Barbosa, E.M.; Netto, M.M.; Caldeira, J.R.; Katayama, M.L.; Soares, F.A.; Oliveira, C.T.; Reis, L.F.; Kaiano, J.H.; Camargo, L.P.; Vêncio, R.Z.; Snitcovsky, I.M.; Makdissi, F.B.; e Silva, P.J.; Góes, J.C.; Brentani, M.M. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005, 11(20), 7434-7443.
9. Hannemann, J.; Oosterkamp, H.M.; Bosch, C.A.J.; Velds, A.; Wessels, L.F.; Loo, C.; Rutgers, E.J.; Rodenhuis, S.; van de Vijver, M.J. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005, 23(15), 3331-3342. (Pubitemid 46243477)
10. Dressman, H.K.; Hans, C.; Bild, A.; Olson, J.A.; Rosen, E.; Marcom, P.K.; Liotcheva, V.B.; Jones, E.L.; Vujaskovic, Z.; Marks, J.; Dewhirst, M.W.; West, M.; Nevins, J.R.; Blackwell, K. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006, 12(3 Pt 1), 819-826. (Pubitemid 43259863)
11. Thuerigen, O.; Schneeweiss, A.; Toedt, G.; Warnat, P.; Hahn, M.; Kramer, H.; Brors, B.; Rudlowski, C.; Benner, A.; Schuetz, F.; Tews, B.; Eils, R.; Sinn, H.P.; Sohn, C.; Lichter, P. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006, 24(12), 1839-1845. (Pubitemid 46638981)
12. Modlich, O.; Prisack, H.B.; Munnes, M.; Audretsch, W.; Bojar, H. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004, 10(19), 6418-6431. (Pubitemid 39346536)
13. Sotiriou, C.; Desmedt, C. Gene expression profiling in breast cancer. Ann Oncol 2006, 17(Suppl 10), x259-262. (Pubitemid 44542019)
14. Luporsi, E.; Vanlemmens, L.; Coudert, B. Six cycles of FEC 100 vs six cycles of epirubicin/docetaxel as neoadjuvant chemotherapy in operable breast cancer patients: results of a randomized phase II trial of GIREC S01. Presented at the 36th Annual ASCO Meeting. Cancer Conf Highlights 2000, 4, 2-4.
15. Chollet, P.; Amat, S.; Cure, H.; de Latour, M.; Le Bouedec, G.; Mouret-Reynier, M.A.; Ferriere, J.P.; Achard, J.L.; Dauplat, J.; Penault-Llorca, F. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86(7), 1041-1046. (Pubitemid 34441058)
16. Arnal, M.; Franco, N.; Fargeot, P.; Riedinger, J.M.; Brunet-Lecomte, P.; Lizard-Nacol, S. Enhancement of mdr1gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 2000, 61(1), 13-20. (Pubitemid 30440546)
17. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001, 25(4), 402-408. (Pubitemid 34164012)
18. Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, O.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature 2000, 406(6797), 747-752. (Pubitemid 30671230)
19. Troester, M.A.; Hoadley, K.A.; Sørlie, T.; Herbert, B.S.; Børresen-Dale, A.L.; Lønning, P.E.; Shay, J.W.; Kaufmann, W.K.; Perou, C.M. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res 2004, 64(12), 4218-4226. (Pubitemid 38802426)
20. Gianni, L.; Zambetti, M.; Clark, K.; Baker, J.; Cronin, M.; Wu, J.; Mariani, G.; Rodriguez, J.; Carcangiu, M.; Watson, D.; Valagussa, P.; Rouzier, R.; Symmans, W.F.; Ross, J.S.; Hortobagyi, G.N.; Pusztai, L.; Shak, S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23(29), 7265-7277. (Pubitemid 46202341)
21. Minna, J.D.; Girard, L.; Xie, Y. Tumor mRNA expression profiles predicts responses to chemotherapy. J Clin Oncol 2007, 25(28), 4329-4336. (Pubitemid 350013833)
22. Sotiriou, C.; Piccart, M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007, 7(7), 545-553.
23. Korn, E.L.; McShane, L.M.; Troendle, J.F.; Rosenwald, A.; Simon, R. Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002, 86(7), 1093-1096. (Pubitemid 34438080)
24. Dupuy, A.; Simon, R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007, 99(2), 147-157.
25. Espinosa, E.; Fresno-Vara, J.A.; Redondo, A.; Sánchez, J.J.; Hardisson, D.; Zamora, P.; Pastrana, F.G.; Cejas, P.; Martínez, B.; Suárez, A.; Calero, F.; Barón, M.G. Breast cancer prognosis determined by gene expression profiling: a quantitative reverse transcriptase polymerase chain reaction study. J Clin Oncol 2005, 23(29), 7278-7285.
26. Ioannidis, J.P.A. Microarrays and molecular research: noise discovery? Lancet 2005, 365(9458), 454-455.
27. Michiels, S.; Koscielny, S.; Hill, C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005, 365(9458), 488-492. (Pubitemid 40215731)
28. Febbo, P.G.; Kantoff, P.W. Noise and bias in microarray analysis of tumour specimens. J Clin Oncol 2006, 24(23), 3719-3720.
29. Bellamy, C.O. p53 and apoptosis. Br Med Bull 1997, 53(3), 522-538.
30. Morse, D.L.; Gray, H.; Payne, C.M.; Gillies, R.J. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005, 4(10), 1495-1504. (Pubitemid 41556431)
31. Harris, S.R.; Schoeffner, D.J.; Yoshiji, H.; Thorgeirsson, U.P. Tumor-growth-enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett 2002, 179(1), 95-101.